Skip to main content
TTrialFinderData
TrialFinderData is for informational purposes only and does not provide medical advice. Always talk to your doctor.

Updated May 2026 · ClinicalTrials.gov

First Affiliated Hospital of Fujian Medical University

7 clinical trials · 7 recruiting · OTHER

First Affiliated Hospital of Fujian Medical University has 7 clinical trials registered on ClinicalTrials.gov, with 7 actively recruiting participants. The trials listed below cover 9 conditions across the phases listed in the sidebar. Always discuss any specific trial with your physician before contacting a study site.

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.

About First Affiliated Hospital of Fujian Medical University\'s Trial Portfolio

First Affiliated Hospital of Fujian Medical University is a non-industry sponsor (academic medical center, hospital, foundation, or research network). Non-industry sponsors often investigate novel approaches, rare conditions, and behavioral or surgical interventions that commercial sponsors may not prioritize.

7 of First Affiliated Hospital of Fujian Medical University's 7 registered trials are currently recruiting — roughly 100% of the portfolio. A high recruiting share usually points to an active research pipeline with multiple programs at the enrollment stage.

First Affiliated Hospital of Fujian Medical University's research footprint spans Prostate Cancer (Adenocarcinoma) (2 trials), prostate-cancer-screening (1), and psma-pet (1) as the top three conditions. The full condition list, sorted by trial count, is in the sidebar.

Not Applicable is the largest single phase in First Affiliated Hospital of Fujian Medical University's portfolio at 43% of registered trials. The full phase breakdown appears in the sidebar.

Trials by First Affiliated Hospital of Fujian Medical University

RECRUITINGNCT06923657

PSMA PET/MRI-Guided Prostate Biopsy for PI-RADS ≤3 and Prior Negative Biopsy

The goal is to provide more accurate diagnostic tools and optimized diagnostic workflows for clinically suspected prostate cancer patients with prior negative biopsies, improving...

Sponsor: First Affiliated Hospital of Fujian Medical UniversityEnrolling: 2301 location
Prostate Cancer ScreeningPSMA-PET
RECRUITINGPhase 1 / Phase 2NCT07363382

The Value of GRPR PET Imaging for Diagnosis and Staging in Prostate Cancer

The gastrin-releasing peptide receptor (GRPR) is highly expressed in prostate cancer (77%-100%). Numerous studies have confirmed that GRPR PET imaging has emerged as a significant...

Sponsor: First Affiliated Hospital of Fujian Medical UniversityEnrolling: 61 location
Prostate Cancer (Adenocarcinoma)
RECRUITINGEarly Phase 1NCT06612580

68Ga-AAZTA-NI-093 PET/CT: First-in-human Study

68Ga-AAZTA-093 is a novel radiotracer incorporating a hypoxia sensitive nitroimidazole(NI)-moiety and a PSMA-targeting. In this study, we observed the safety, biodistribution,...

Sponsor: First Affiliated Hospital of Fujian Medical UniversityEnrolling: 101 location
Prostate Cancer (Adenocarcinoma)
RECRUITINGNCT06977906

Improved Robotic-Assisted Radical Prostatectomy for Locally Advanced Prostate Cancer: Bladder Suspension and...

This study is a prospective, single-center clinical trial. It aims to establish an improved robotic-assisted radical prostatectomy for treating locally advanced prostate cancer....

Sponsor: First Affiliated Hospital of Fujian Medical UniversityEnrolling: 3001 location
Robotic-Assisted Radical ProstatectomyLocally Advanced Prostate CancerBladder Suspension
RECRUITINGNCT04008329

A Registered Cohort Study on Amyotrophic Lateral Sclerosis

Amyotrophic lateral sclerosis (ALS) is a kind of motor neuron degeneration disorder without effective therapy. This registered cohort study will provide further insights into the...

Sponsor: First Affiliated Hospital of Fujian Medical UniversityEnrolling: 20001 location
Amyotrophic Lateral Sclerosis
RECRUITINGNCT07513844

Optimizing Parameters of Low-Intensity Focused Ultrasound for Pallidal Modulation in Huntington's Disease

The purpose of this research study is to determine the optimal pulse repetition frequency of low-intensity focused ultrasound that is safe and effective in improving motor...

Sponsor: First Affiliated Hospital of Fujian Medical UniversityEnrolling: 241 location
Huntington Disease
RECRUITINGNCT07257562

Combined Use of Bacteroides Fragilis and BCAAs on HBsAg Clearance

The goal of this prospective observational study is to determine the effects of concomitant administration of Bacteroides fragilis and Branched-Chain Amino Acids on hepatitis B...

Sponsor: First Affiliated Hospital of Fujian Medical UniversityEnrolling: 401 location
Chronic Hepatitis B

How to Approach a Trial Listing

Each trial card above links to a dedicated page with the official ClinicalTrials.gov data plus a plain-English translation of the eligibility criteria. We translate technical terminology (ECOG performance status, hepatic function values, exclusionary lab thresholds) into language that a patient or caregiver can understand, but the original clinical text and the live ClinicalTrials.gov record always govern any actual eligibility decision.

Before contacting a trial site, write down questions for your treating physician using the framework on our 25 Questions guide. Discuss whether the trial fits your treatment plan, what the time commitment looks like, and whether your insurance will cover the standard-of-care portions. Trials are not a substitute for a treatment plan — they are an addition that needs medical guidance to evaluate.

Authoritative Resources

Verify any trial registration directly on ClinicalTrials.gov. For background on the FDA approval pathway that Phase 3 trials feed into, see the FDA drug approval process. For cancer-specific trial guidance, the National Cancer Institute publishes patient-oriented overviews. For global trial registrations beyond the U.S., the WHO ICTRP aggregates registries from around the world.

Frequently Asked Questions

How many clinical trials does First Affiliated Hospital of Fujian Medical University have on ClinicalTrials.gov?

First Affiliated Hospital of Fujian Medical University has 7 clinical trials registered on the federal ClinicalTrials.gov registry, of which 7 are actively recruiting participants right now. These counts come directly from the ClinicalTrials.gov API and are updated as the registry changes.

What conditions does First Affiliated Hospital of Fujian Medical University study?

First Affiliated Hospital of Fujian Medical University's registered trials cover 9 conditions on ClinicalTrials.gov, led by Prostate Cancer (Adenocarcinoma) (2 trials), prostate-cancer-screening (1 trial), psma-pet (1 trial), Robotic-Assisted Radical Prostatectomy (1 trial), locally-advanced-prostate-cancer (1 trial). The complete condition list appears in the sidebar of this page; each condition links to a page listing every recruiting trial in that area, regardless of sponsor.

How do I join a First Affiliated Hospital of Fujian Medical University clinical trial?

Joining a clinical trial is a medical decision that should always involve your treating physician. Each trial page on this site includes the eligibility criteria translated into plain English alongside the official clinical text, plus the contact information that the sponsor has registered with ClinicalTrials.gov. Bring the trial information to your doctor before reaching out — they can review the full inclusion and exclusion criteria against your medical history and help you decide whether to pursue screening.

What does the trial phase mean?

Phase 1 trials test safety and dosing in small groups (often 20–80 healthy volunteers or patients). Phase 2 trials evaluate efficacy and side effects in larger groups (100–300 patients with the target condition). Phase 3 trials confirm efficacy and monitor safety in the largest groups (300–3,000+ patients) and form the basis of an FDA approval submission. Phase 4 studies happen after a treatment is approved, monitoring long-term safety and effectiveness in real-world use. Some trials register without a phase — common for device, behavioral, or observational studies.

Where does this trial data come from?

All trial data is pulled directly from the ClinicalTrials.gov API v2, the official federal trial registry maintained by the National Library of Medicine at NIH. Under FDAAA 801, most U.S. drug and device trials are required to register, making ClinicalTrials.gov the most comprehensive source. Sponsors are responsible for keeping their listings current; trial status can shift between data refreshes.

How This Sponsor Page Is Built

Every count on this page is derived directly from ClinicalTrials.gov API v2 records. Trial counts include all trials currently registered to this sponsor; the recruiting count reflects trials with status "Recruiting" or equivalent. Plain-English eligibility translations on each linked trial page preserve the original clinical text alongside an accessible version. Read the full methodology for the data pipeline and limitations.

Source: ClinicalTrials.gov API v2, maintained by the National Library of Medicine at NIH. Public domain. Cite as: "TrialFinderData. Data: ClinicalTrials.gov."

Medical disclaimer: This page is informational, not medical advice. Talk to your doctor about whether a clinical trial is right for you.

Last updated 2026-05-08 · 7 trials tracked for First Affiliated Hospital of Fujian Medical University.

For this entity, the underlying data on this page comes from the NIH ClinicalTrials.gov registry. The breakdown above is the federal record; the paragraphs below add the per-entity context that makes the headline numbers usable for a real decision rather than just a data lookup.

The methodology behind every numeric value on this page is publicly documented on the the NIH ClinicalTrials.gov registry portal and described in detail on this site’s methodology page. Refresh cadence varies by underlying series; the page surfaces the as-of date for each number so readers can trace any figure back to the source release.

Practical use of this page is in combination with the comparison and ranking pages elsewhere on the site, which surface the same data for this entity’s peers within active and historical clinical trials. A single-entity reading without peer context can be misleading when an entity is an outlier on one axis but typical on another.